Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568787 · ClinicalTrials.gov registry record · NA
The Effect of an RBAC Supplement (BRM4) on NAFLD
A NA study of Non-alcoholic Fatty Liver Disease, sponsored by University of Miami.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT02568787: Completed NA study of Non-alcoholic Fatty Liver Disease, sponsored by University of Miami.
NCT02568787 is a NA study of Non-alcoholic Fatty Liver Disease that has completed, run by University of Miami. The registered enrollment target is 23 participants, below the 177-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02568787, a NA study of Non-alcoholic Fatty Liver Disease, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the effects of Rice Bran Arabinoxylan Compound (RBAC) on outcome variables in persons with non-alcoholic fatty liver disease (NAFLD). This nutritional supplement is made from a water soluble extract of rice bran that has been partially hydrolyzed by the action of a natural enzyme complex extracted from Shiitake mushroom.
Primary Outcome
Liver function tests as defined by serum ALT, AST and ALP
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT rice bran arabinoxylan compound (RBAC)
Study Locations (1)
Florida
- University of Miami Miller School of Medicine, Soffer Clinical Research Center, Department of Psychiatry & Behavioral Sciences - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-06-10 |
| Phase | NA |
What the finished NCT02568787 record still lists
NCT02568787 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 177-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02568787 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02568787 about?
NCT02568787 is a clinical study titled "The Effect of an RBAC Supplement (BRM4) on NAFLD". The purpose of this study is to investigate the effects of Rice Bran Arabinoxylan Compound (RBAC) on outcome variables in persons with non-alcoholic fatty liver disease (NAFLD). This nutritional supplement is made from a water soluble extract of rice bran that has been partially hydrolyzed by the ac...
What is the current status of trial NCT02568787?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2016-05. Estimated completion is 2017-06-10.
What conditions does trial NCT02568787 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT02568787?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), rice bran arabinoxylan compound (RBAC) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02568787?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02568787 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02568787's enrollment target sits among peer trials
23 53rd of 57 higher than 5 of 57 other Non-alcoholic Fatty Liver Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Fatty Liver Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intermittent Fasting for NAFLD in Adults
RECRUITING · NA
-
Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents
RECRUITING · NA
-
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
RECRUITING · NA
-
The Olmsted NAFLD Epidemiology Study (TONES)
RECRUITING · NA
-
Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
RECRUITING · NA
-
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia